• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双硫仑靶向HER2阳性乳腺癌中的癌症干细胞样特性及HER2/Akt信号通路。

Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.

作者信息

Kim Ji Young, Cho Youngkwan, Oh Eunhye, Lee Nahyun, An Hyunsook, Sung Daeil, Cho Tae-Min, Seo Jae Hong

机构信息

Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.

Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.

出版信息

Cancer Lett. 2016 Aug 28;379(1):39-48. doi: 10.1016/j.canlet.2016.05.026. Epub 2016 May 26.

DOI:10.1016/j.canlet.2016.05.026
PMID:27238567
Abstract

HER2-positive breast tumors are known to harbor cancer stem-like cell populations and are associated with an aggressive tumor phenotype and poor clinical outcomes. Disulfiram (DSF), an anti-alcoholism drug, is known to elicit cytotoxicity in many cancer cell types in the presence of copper (Cu). The objective of the present study was to investigate the mechanism of action responsible for the induction of apoptosis by DSF/Cu and its effect on cancer stem cell properties in HER2-positive breast cancers in vitro and in vivo. DSF/Cu treatment induced apoptosis, associated with a marked decrease in HER2, truncated p95HER2, phospho-HER2, HER3, phospho-HER3 and phospho-Akt levels, and p27 nuclear accumulation. This was accompanied by the eradication of cancer stem-like populations, concomitant with the suppression of aldehyde dehydrogenase 1 (ALDH1) activity and mammosphere formation. DSF administration resulted in a significant reduction in tumor growth and an enhancement of apoptosis, as well as HER2 intracellular domain (ICD) and ALDH1A1 downregulation. Our results demonstrate that DSF/Cu induces apoptosis and eliminates cancer stem-like cells via the suppression of HER2/Akt signaling, suggesting that DSF may be potentially effective for the treatment of HER2-positive cancers.

摘要

已知HER2阳性乳腺肿瘤含有癌干细胞样细胞群体,并与侵袭性肿瘤表型和不良临床结果相关。双硫仑(DSF)是一种抗酒精中毒药物,已知在铜(Cu)存在的情况下,它会在许多癌细胞类型中引发细胞毒性。本研究的目的是研究DSF/Cu诱导细胞凋亡的作用机制及其对HER2阳性乳腺癌体外和体内癌干细胞特性的影响。DSF/Cu处理诱导细胞凋亡,这与HER2、截短的p95HER2、磷酸化HER2、HER3、磷酸化HER3和磷酸化Akt水平的显著降低以及p27核积累有关。这伴随着癌干细胞样群体的根除,同时醛脱氢酶1(ALDH1)活性和乳腺球形成受到抑制。给予DSF导致肿瘤生长显著减少,细胞凋亡增加,以及HER2细胞内结构域(ICD)和ALDH1A1下调。我们的结果表明,DSF/Cu通过抑制HER2/Akt信号传导诱导细胞凋亡并消除癌干细胞样细胞,这表明DSF可能对HER2阳性癌症的治疗具有潜在疗效。

相似文献

1
Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.双硫仑靶向HER2阳性乳腺癌中的癌症干细胞样特性及HER2/Akt信号通路。
Cancer Lett. 2016 Aug 28;379(1):39-48. doi: 10.1016/j.canlet.2016.05.026. Epub 2016 May 26.
2
Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.氟苯达唑通过靶向 HER2 阳性乳腺癌中的癌症干细胞样特性和 HER2 信号转导克服曲妥珠单抗耐药性。
Cancer Lett. 2018 Jan 1;412:118-130. doi: 10.1016/j.canlet.2017.10.020. Epub 2017 Nov 5.
3
Disulfiram/copper targets stem cell-like ALDH population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway.双硫仑/铜通过抑制醛脱氢酶1A1(ALDH1A1)和刺猬信号通路来靶向多发性骨髓瘤的干细胞样醛脱氢酶群体。
J Cell Biochem. 2018 Aug;119(8):6882-6893. doi: 10.1002/jcb.26885. Epub 2018 Apr 17.
4
Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.双硫仑抑制三阴性乳腺癌细胞中的癌症干细胞样特性和STAT3信号传导。
Biochem Biophys Res Commun. 2017 May 13;486(4):1069-1076. doi: 10.1016/j.bbrc.2017.03.164. Epub 2017 Apr 1.
5
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.通过使用一种新型塞来昔布衍生的磷酸肌醇依赖性激酶-1抑制剂克服HER2过表达乳腺癌细胞中的曲妥珠单抗耐药性。
Mol Pharmacol. 2006 Nov;70(5):1534-41. doi: 10.1124/mol.106.023911. Epub 2006 Aug 3.
6
Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy.双硫仑/铜通过诱导 Bip 介导的细胞凋亡和抑制自噬对骨髓增生异常综合征表现出强大的细胞毒性作用。
Eur J Pharmacol. 2021 Jul 5;902:174107. doi: 10.1016/j.ejphar.2021.174107. Epub 2021 Apr 16.
7
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.两种临床药物去泛素化酶抑制剂金诺芬和乙醛脱氢酶抑制剂双硫仑在体外和体内均引发协同抗肿瘤作用。
Oncotarget. 2016 Jan 19;7(3):2796-808. doi: 10.18632/oncotarget.6425.
8
Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.双硫仑调节活性氧积累并协同克服乳腺癌细胞系的顺铂耐药性。
Biomed Pharmacother. 2019 May;113:108727. doi: 10.1016/j.biopha.2019.108727. Epub 2019 Mar 12.
9
The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.NVP-BKM120 联合曲妥珠单抗或 RAD001 协同抑制体内乳腺癌干细胞的生长。
Oncol Rep. 2016 Jul;36(1):356-64. doi: 10.3892/or.2016.4799. Epub 2016 May 10.
10
Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.铜通过表皮生长因子受体/原癌基因酪氨酸蛋白激酶/血管内皮生长因子途径增强双硫仑在胶质瘤中的抗血管生成活性。
Cancer Lett. 2015 Dec 1;369(1):86-96. doi: 10.1016/j.canlet.2015.07.029. Epub 2015 Aug 5.

引用本文的文献

1
Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy.用于癌症诊断与治疗的硫化铜纳米颗粒的最新进展
Mater Today Bio. 2025 Aug 13;34:102197. doi: 10.1016/j.mtbio.2025.102197. eCollection 2025 Oct.
2
The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.癌症中铜及铜死亡的分子机制与治疗前景
Signal Transduct Target Ther. 2025 May 9;10(1):149. doi: 10.1038/s41392-025-02192-0.
3
ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review).
乳腺癌中的乙醛脱氢酶1A1:克服治疗耐药性的潜在靶点(综述)
Oncol Lett. 2025 Mar 4;29(5):213. doi: 10.3892/ol.2025.14959. eCollection 2025 May.
4
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.靶向起始因子以激活铁死亡和铜死亡用于乳腺癌治疗:临床应用的进展与可能性
Front Pharmacol. 2025 Jan 10;15:1493188. doi: 10.3389/fphar.2024.1493188. eCollection 2024.
5
Cuproptosis: a promising new target for breast cancer therapy.铜死亡:乳腺癌治疗的一个有前景的新靶点。
Cancer Cell Int. 2024 Dec 19;24(1):414. doi: 10.1186/s12935-024-03572-2.
6
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.针对癌症治疗的铜死亡:机制见解与临床展望。
J Hematol Oncol. 2024 Aug 16;17(1):68. doi: 10.1186/s13045-024-01589-8.
7
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes.视黄酸核受体信号在癌症和代谢综合征中的致病作用。
J Exp Med. 2024 Sep 2;221(9). doi: 10.1084/jem.20240519. Epub 2024 Aug 12.
8
Post-translational modifications: The potential ways for killing cancer stem cells.翻译后修饰:杀死癌症干细胞的潜在途径。
Heliyon. 2024 Jul 4;10(14):e34015. doi: 10.1016/j.heliyon.2024.e34015. eCollection 2024 Jul 30.
9
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review.HER2 阳性乳腺癌中的 HER2/PI3K/AKT 通路:综述。
Medicine (Baltimore). 2024 Jun 14;103(24):e38508. doi: 10.1097/MD.0000000000038508.
10
Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing.重振癌症治疗:探索药物重新利用的作用。
Cancers (Basel). 2024 Apr 11;16(8):1463. doi: 10.3390/cancers16081463.